Landeskrankenanstalten-Betriebsgesellschaft Kabeg
- Address
- lock Available on a paid plan
Landeskrankenanstalten-Betriebsgesellschaft Kabeg - Comprehensive Multi-Specialty Research Center
Landeskrankenanstalten-Betriebsgesellschaft Kabeg is a leading clinical research institution conducting advanced studies across a diverse range of medical specialties. The center demonstrates particular expertise in oncology clinical trials, including investigations into novel immunotherapy combinations for bladder cancer, breast cancer, lung cancer, hepatocellular carcinoma, and head and neck cancers. The facility also maintains robust research programs in gastroenterological conditions, cardiovascular diseases, and neurological disorders.
- Advanced oncology research including muscle-invasive bladder cancer, early and metastatic breast cancer, non-small cell lung cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, ovarian cancer, and squamous cell carcinoma of the head and neck
- Inflammatory bowel disease studies focusing on ulcerative colitis and Crohn's disease with novel therapeutic approaches
- Cardiovascular and metabolic disease research including heart failure, atherosclerotic disease in end-stage kidney disease, and acute myocardial infarction
- Specialized studies in rare liver diseases (alpha-1 antitrypsin deficiency), celiac disease, progressive fibrosing interstitial lung diseases, multiple sclerosis, chronic and episodic migraine, and ophthalmological conditions including age-related macular degeneration
The research center's extensive portfolio demonstrates a commitment to cutting-edge therapeutic development, with particular emphasis on immunotherapy and targeted biologics. The facility participates in phase I through phase III clinical trials, evaluating novel therapeutic combinations, biosimilars, and digital health solutions. Kabeg's research spans both early-phase drug development and large-scale pivotal trials, positioning the center as a versatile contributor to precision medicine and innovative treatment paradigms across multiple disease areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 104 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 95 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Amgen Inc.3active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Landeskrankenanstalten-Betriebsgesellschaft Kabeg
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 104 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.